Jove
Visualize
Contact Us

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Partner change, birth interval and risk of pre-eclampsia: a paradoxical triangle.

Paediatric and perinatal epidemiology·2007
Same author

Partner change and perinatal outcomes: a systematic review.

Paediatric and perinatal epidemiology·2007
Same author

A controversial tumor marker: is SM22 a proper biomarker for gastric cancer cells?

Journal of proteome research·2007
Same author

A strategy for high-throughput analysis of levosimendan and its metabolites in human plasma samples using sequential negative and positive ionization liquid chromatography/tandem mass spectrometric detection.

Rapid communications in mass spectrometry : RCM·2007
Same author

[Leukemic cell apoptosis induced by anti-human DR5 monoclonal antibody mDRA-6].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology·2007
Same author

[Infection of intervertebral space and the interventional therapy].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences·2007
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 21, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Hepatitis E vaccine development: a 14 year odyssey.

Ting Wu1, Shao-Wei Li, Jun Zhang

  • 1National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.

Human Vaccines & Immunotherapeutics
|June 16, 2012
PubMed
Summary

The first prophylactic hepatitis E vaccine (HEV), Hecolin®, was approved in China in 2011. This commentary summarizes its 14-year development, highlighting the successful recombinant virus-like particle (VLP) technology.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Experiment Videos

Last Updated: May 21, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Area of Science:

  • Vaccinology
  • Hepatitis E Virus (HEV) Research
  • Biotechnology

Background:

  • Hepatitis E virus (HEV) infection poses a significant public health challenge globally.
  • The development of a prophylactic vaccine against HEV has been a long-standing goal in infectious disease research.
  • Existing vaccine development faced challenges in antigen production and demonstration of efficacy.

Purpose of the Study:

  • To summarize the key milestones in the 14-year development of the first prophylactic HEV vaccine.
  • To highlight the innovative recombinant virus-like particle (VLP) technology used for vaccine antigen production.
  • To present the successful demonstration of vaccine safety and efficacy in large-scale clinical trials.

Main Methods:

  • Development of a recombinant virus-like particle (VLP) based antigen.
  • Utilizing an E. coli production platform for large-scale antigen manufacturing.
  • Conducting a large-scale phase III clinical trial to assess safety and efficacy.

Main Results:

  • Successful commercial-scale production of a recombinant VLP-based HEV antigen with virion-like epitopes.
  • Demonstration of the safety of the HEV vaccine in clinical trials.
  • Demonstration of the efficacy of the HEV vaccine in preventing HEV infection and associated disease.

Conclusions:

  • The development of Hecolin®, the first prophylactic HEV vaccine, represents a major advancement in infectious disease prevention.
  • The recombinant VLP technology employed is a viable and scalable platform for vaccine development.
  • The vaccine's approval and demonstrated safety and efficacy pave the way for wider public health impact.